Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: NEO stock price vs LGND: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LGND's multiple
Needs LGND P/S.
Implied fair value · at NEO's multiple
Needs NEO P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NEO FY 2025 (ended Dec 31, 2025) · LGND FY 2025 (ended Dec 31, 2025).
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
NeoGenomics, Inc. · implied price per share
Bear
-$7.04
Base
-$8.29
Bull
-$9.53
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.64x
0.25x
Net debt / EBITDA
Leverage against operating earnings
-11.21x
-2.31x
Cash and equivalents
Liquid reserves on the balance sheet
$159.62M
$733.52M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
Royalty Pharma plc
NEO vs RPRX
Sarepta Therapeutics, Inc.
NEO vs SRPT
INCYTE CORP
NEO vs INCY
EXELIXIS, INC.
NEO vs EXEL
$538.20M
$252.03M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
